Effects of Sevoflurane and Desflurane on Some Biochemical Parameters

Mustafa Yöntem*,1, Aydan Akkaya2, Suleyman Kaleli3, Fatih Erci1, Fatma Emel Kocak4

1Necmettin Erbakan University, Faculty of Science, Department of Biotechnology, Konya, Turkey
2Dumlupınar University, Faculty of Science, Department of Biology, Kutahya, Turkey
3Sakarya University, Faculty of Medicine, Department of Medical Biology, Sakarya, Turkey
4Dumlupınar University, Faculty of Medicine, Department of Medical Biochemistry, Kutahya, Turkey

ABSTRACT:
General anesthesia is the administration of certain anesthetics that enable a patient to tolerate surgical conditions. This study was aimed to better explain effects of sevoflurane, and desflurane, inhaled anesthetics, on liver and kidney functions by determining postoperative changes of some biochemical parameters. In this study, 35 patients suited physical status of American Society of Anesthesiologists (ASA) I-II groups were included. Patients with normal renal and hepatic functions were randomly allocated into two groups according to the inhalation agents used. These groups are group of sevoflurane (group S) and group of desflurane (group D). In all groups, general anesthesia was induced with thiopentone and cisatracurium and maintained with 50 % N2O - 50 % oxygen and one of the two volatile agents (desflurane, and sevoflurane). Levels of serum BUN, Urea, Creatinine, AST, ALT were determined in blood samples. Levels of AST in group S and group D increased in post-operation. While there was no significant difference in group D, there was statistically significant difference in group S. The primary effects of volatile anesthetics were on the biochemical parameters of liver postoperatively. Especially, in people with liver disease, it may be considered that desflurane can be a good alternative to sevoflurane in general anesthesia.

Keywords: Anesthetics, Sevoflurane, Desflurane, Biochemical parameters.
lether family that small change results in significant physical alterations. Dose-dependent hypotension, respiratory depression, increase in cerebral pressure, abnormal cardiac rhythm, and myocardial ischemia may occur. Particularly in children, increased secretion of saliva, cough, laryngeal, and bronchial spasms, nausea, vomiting, and hepatitis may be seen independently of the dose. It has been reported that like other halogenated anesthetics, desflurane reacts with dry carbon dioxide absorbents, and generates carbon monoxide. At high concentrations, heart rate, central venous pressure, and pulmonary artery pressure increases \[^{2,5 - 9}\].

The aim of this study was to ascertain the effects of sevoflurane, and desflurane, recently available inhalation anesthetic agents, on liver, and kidney functions.

**MATERIALS AND METHODS**

**Subjects**

The study was conducted in Dumlupinar University Evliya Celebi Research, and Education Hospital among the patients with age range of 25-65 years whose physical statuses were consistent with ASA I-II group, and who were planned to have elective surgeries because of different diagnoses, and decided to be eligible for general anesthesia by specialist physicians.

Evliya Celebi Research and Education Hospital has 750 bed capacity, and 40 medical departments. Our study was conducted with blood specimens collected from totally 35 patients (11 men, 24 women). The patients who had problems during surgery or those who required additional medical agents were excluded from the study. The patients were randomly divided into two groups according to the inhalation agent used. The Group S was consisted of 18 individuals (6 male patients, and 12 female patients), and the Group D was consisted of 17 individuals (5 male patients, and 12 female patients). The study was carried out in accordance with Declaration of Helsinki. Ethical committee approval was received from the local Human Research Ethics Committee. Written informed consent was obtained from all subjects.

**Methods**

All patients were examined before, and prepared to the surgery with determination of the premedication. The patients were given premedication intramuscularly with 0.15 mg/kg dose of diazepam, and 0.5 mg of atropine sulfate 30 minutes before the surgery. The induction of anesthesia was done in all patients with the injections of 4-7 mg/kg of thiopental sodium, and 0.15-0.20 mg/kg of cisatracurium, in that order. The concentrations of volatile agents were adjusted to be between 1 to 2% in the sevoflurane group, and between 6 to 8% in the desflurane group. The patients were given preoperatively 3-5 mg/kg of crystalloid serum infusion. Blood specimens were collected at both preoperative, and postoperative 24 h.

For each donor, preoperative, and postoperative venous blood samples were collected into an evacuated serum separator clot activator tubes (Vacuette®, Greiner Bio-One, Kremsmunster, Austria). The venous blood samples were centrifuged at 3500 rpm for 10 minutes at room temperature, and serum samples were separated. Serum blood urea nitrogen (BUN), urea, creatinine, aspartate aminotranspherase (AST), and alanine aminotranspherase (ALT) levels were measured on Roche Cobas c501 analyzer (Roche Diagnostics GmbH, Mannheim, Germany) with original reagents. Controls for both groups were designated within each group.

**Statistical analysis**

Statistical analyses were performed using SPSS software (version 13.0 for Windows; SPSS, Inc, Chicago, IL, USA). Mean values for all variables were compared between study groups using paired t test, and two-tailed distribution analysis. For all statistical tests, P ≤ 0.05 was considered statistically significant.

**RESULTS**

The levels of serum BUN, urea, creatinine, AST, and ALT determined in the preoperative and postoperative venous blood samples obtained from the desflurane group.

<table>
<thead>
<tr>
<th>Groups</th>
<th>N</th>
<th>Mean ± SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>BUN (mg/dl)</td>
<td>Pre-operation</td>
<td>17</td>
</tr>
<tr>
<td></td>
<td>Post-operation</td>
<td>17</td>
</tr>
<tr>
<td>Urea (mg/dl)</td>
<td>Pre-operation</td>
<td>17</td>
</tr>
<tr>
<td></td>
<td>Post-operation</td>
<td>17</td>
</tr>
<tr>
<td>Creatinine (mg/dl)</td>
<td>Pre-operation</td>
<td>17</td>
</tr>
<tr>
<td></td>
<td>Post-operation</td>
<td>17</td>
</tr>
<tr>
<td>AST (U/L)</td>
<td>Pre-operation</td>
<td>17</td>
</tr>
<tr>
<td></td>
<td>Post-operation</td>
<td>17</td>
</tr>
<tr>
<td>ALT (U/L)</td>
<td>Pre-operation</td>
<td>17</td>
</tr>
<tr>
<td></td>
<td>Post-operation</td>
<td>17</td>
</tr>
</tbody>
</table>

Results were expressed as mean ± standard deviation

Table 1. The levels of serum BUN, urea, creatinine, AST and ALT in the desflurane group.
The changes in preoperative and postoperative serum AST levels in both groups were shown in Table 1. Serum AST levels increased arithmetically in both groups. The increase in the Group S was higher than the group D, and was found to be statistically significant (p≤0.05). There was no statistically significant difference between the groups in terms of the increases in AST levels.

**DISCUSSION**

The goal of anesthesia is to ensure a rapid and comfortable anesthetic induction in the patient without any hemodynamic changes, maintenance of preoperative hemodynamic stability, a rapid wake up without undesirable effects and early mobilization [1, 10-13]. Bedi, and Fee denoted that sevoflurane, and desflurane were more advantageous than isoflurane, and halothane [5]. It is disadvantageous that sevoflurane, and desflurane react with soda lime to generate compound A, and CO, and that the patients inhale these products; however, it has been denoted that it was not clear whether these degradation products led to significant problems for the patients [5]. None of the inhalation anesthetics being used today is directly nephrotoxic. However, their metabolites (inorganic fluoride) may cause to renal injury because of their directly nephrotoxic effects.

With halothane, desflurane, and isoflurane, the level of fluorine does not reach to danger limit even in the situations in which their metabolisms are accelerated; in contrast, with enflurane and sevoflurane, fluorine levels may increase after prolonged anesthesia [1, 4, 8, 9, 14]. It is known that sevoflurane generates compound A reacting with CO2 absorbents. The compound A is toxic; its toxic effect on the liver and particularly on the kidneys has been shown in the studies performed with rats. The formation of compound A enhances especially in the situations in which fresh gas flow reduces (low flow), and the temperature increases; and that causes to the formation of compound B and other degradation products [2, 4, 7, 9, 15-17].

In the light of the above data, we planned to ascertain the effects of sevoflurane, and desflurane, volatile anesthetic agents recently become available in our country, on the liver and kidney functions. When we statistically analyzed the results achieved, the change in AST parameter in the Group S was found to be statistically significant (p≤0.05), however, clinically that change was in normal ranges. In the Group D, the change in AST level was not statistically significant (p>0.05). When the changes in ALT parameter were analyzed statistically, there was not any significant difference between the groups, and in in-group comparisons. That in the Group S ALT level tended to increase in comparison with the Group D, although it was not statistically significant, and that in the Group S there was a statistically significant difference in AST made us think that this agent might have a greater impact on the liver.

When the changes in serum BUN, urea, and creatinine values were analyzed statistically, there was not any significant difference between the groups, and in in-group comparisons. That in the Group S ALT level tended to increase in comparison with the Group D, although it was not statistically significant, and that in the Group S there was a statistically significant difference in AST made us think that this agent might have a greater impact on the liver.

**Table 2. The levels of BUN, urea, creatinine, AST and ALT in the sevoflurane group.**

<table>
<thead>
<tr>
<th>Groups</th>
<th>N</th>
<th>Mean ± SD</th>
</tr>
</thead>
<tbody>
<tr>
<td>BUN (mg/dl)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pre-operation</td>
<td>18</td>
<td>12.8±3.30*</td>
</tr>
<tr>
<td>Post-operation</td>
<td>18</td>
<td>11.2±3.04</td>
</tr>
<tr>
<td>Urea (mg/dl)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pre-operation</td>
<td>18</td>
<td>27.4±7.41</td>
</tr>
<tr>
<td>Post-operation</td>
<td>18</td>
<td>24.1±6.79</td>
</tr>
<tr>
<td>Creatinine (mg/dl)</td>
<td>18</td>
<td>0.86±0.16</td>
</tr>
<tr>
<td>AST (U/L)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pre-operation</td>
<td>18</td>
<td>17.6±5.14*</td>
</tr>
<tr>
<td>Post-operation</td>
<td>18</td>
<td>23.2±8.95*</td>
</tr>
<tr>
<td>ALT (U/L)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pre-operation</td>
<td>18</td>
<td>16.6±5.68</td>
</tr>
<tr>
<td>Post-operation</td>
<td>18</td>
<td>17.5±7.59</td>
</tr>
</tbody>
</table>

* Results were expressed as mean ± standard deviation.

*: Superscript letters in the same column (a - b) indicate significant differences (p<0.05).
were insignificant in the groups of sevoflurane and desflurane; that the change in AST level was found to be significant and although the change was higher in the sevoflurane group, there was no statistically significant difference between the groups. In terms of kidney function tests, similar to our study, the authors found the change in serum creatinine levels to be insignificant in the groups; they showed that the decrease in BUN levels was significant in all groups but clinically within normal ranges. Eger et al., in a similar study with sevoflurane and desflurane, found that the change in serum creatinine levels was not significant in both groups; that serum fluoride level was significantly increased with sevoflurane (p<0.001), while there was no significant increase in serum fluoride level with desflurane; the authors demonstrated that there was a significant change in urinary albumin excretion with sevoflurane, that α-GST (α-glutathione-S-transferase) was increased only at the hour 8 in the sevoflurane group, otherwise it was normal and that there were no significant changes in ALT and total bilirubin levels from liver function tests.

Obata et al. researched the effects of high-flow sevoflurane, low-flow sevoflurane and low-flow isoflurane anesthesia on the liver and kidney functions and eventually the authors demonstrated that there were no significant changes in BUN and creatinine levels, as in our study. Similar to our study, among liver function tests, AST and ALT levels were found to be increased and the authors demonstrated that although the increase in AST level was statistically significant, there was no difference between the groups and there was no correlation with the compound A. They found a significant increase in total bilirubin level in all groups, however, the authors demonstrated that there was no difference between the groups and the changes in LDH and ALP levels were insignificant. The authors highlighted that the effects of sevoflurane on the kidneys and on the liver were remarkable in low-flow anesthesia practices in which the fresh gas flow reduced. Goldberg et al. demonstrated that low-flow sevoflurane anesthesia led to a significant increase in urinary albumin, glucose, α-GST and compound A excretion. In a similar study, Conzen et al. achieved similar results about the effect of low-flow sevoflurane and isoflurane anesthesia on the kidney functions, and the authors demonstrated that the change in the serum fluoride levels was significant in the sevoflurane group. The same study was done by Abdel-Latif et al. and they also achieved similar results. In another study, Story et al. researched the effects of sevoflurane, isoflurane and propofol on the creatinine levels among the patients with cardiac disorders and they demonstrated that the increase in the sevoflurane group was higher than all other groups although there were small differences between the groups. Kharasch et al. studied the effects of isoflurane and sevoflurane on the liver and kidney functions and similarly they demonstrated that the changes in AST, ALT and renal function tests were statistically insignificant and there was no correlation between the change and the increase in the level of compound A. Iyer et al., in a study with rats, denoted that the urinary glucose and urea levels were significantly increased when the compound A level exceeded 150 ppm, and similarly statistically significant changes in BUN levels were observed.

In a study with 51 patients with known renal disorders, Litz et al. researched the effects of desflurane and isoflurane on the renal response. They demonstrated that desflurane and isoflurane did not result in statistically significant changes in BUN, creatinine and creatinine clearance in the patients with renal dysfunction. In a study, Bauer et al. demonstrated that under desflurane and isoflurane anesthesia at 0.75 MAC for 1 hour, the liver microcirculation was not affected in comparison with pentobarbital. Demirel et al. researched the histopathologic effects of inhalation anesthetics on the liver in the mice and they found liver damage in 3 mice from the control group (n=20), in the sevoflurane group (n=20), in 17 mice from the isoflurane group (n=20) and in 20 mice from the halothane group (n=20). They reported that sevoflurane was safer than isoflurane and halothane, nevertheless liver damage was observed. In conclusion, in the light of the data that we achieved, we think that volatile anesthetic agents affect the functions of the liver and the kidney, that desflurane, which is less metabolized, should be preferred particularly for the patients with liver disorders and that it is necessary for patients’ safety to disclose thoroughly the effects of the inhalation anesthetics with further studies about this issue.

REFERENCES

[8] Hobbhahn J. Are inhaled anaesthetics still toxic? Refresher Courses,
European Society of Anesthesiologists. Regensburg/ Germany 3(RC 1)
2000.
1998. (in Turkish)
[10]Burrows DL, Nicolaides A, Stephens GC, Ferslew KE. The distribu-
tion of sevoflurane in a sevoflurane induced death. J Forensic Sci
macology. The Royal College of Anaesthetists Bulletin 13 May,2002:623-
626.
at: http://lokman.cum.edu.tr/anestezi/anestezinot/index.htm. (in Turkish)
si 2003;13:29-34.
R, et al. Dose of compound A, not sevoflurane, determines changes in
the biochemical markers of renal injury in healthy volunteers. Anesth
ami W. Long-duration low-flow sevoflurane and isoflurane effects on
postoperative renal and hepatic function. Anesth Analg 2001;93:1511-
1520.
The effects of prolonged low-flow sevoflurane anesthesia on renal and
[17]Stabernack CR, Eger EI, Warnken UH, Förster H, Hanks DK, Fer-
rell LD. Sevoflurane degradation by carbon dioxide absorbents may
produce more than one nephrotoxic compound in rats. Can J Anaesth
[18]Ebert TJ, Arain SR. Renal responses to low-flow desflurane, sevoflu-
Dose-related biochemical markers of renal injury after sevoflurane
versus desflurane anesthesia in volunteers. Anesth Analg 1997;85:
1154-1163.
[20]Conzen PF, Kharasch ED, Czerner SF, Artru AA, Reichle FM, Mi-
chalowski P, et al. Low-flow sevoflurane compared with low-flow isoflu-
rane anesthesia in patients with stable renal insufficiency. Anesthesiol-
gy 2002;97:578-584.
[21]Abdel-Latif MM, Elgammal SA. Serum fluoride ion and renal func-
tion after prolonged sevoflurane or isoflurane anaesthesia. Egyptian
[22]Story DA, Poustie S, Liu G, McNicol PL. Changes in plasma creati-
nine concentration after cardiac anesthesia with isoflurane, propofol,
or sevoflurane: A randomized clinical trial. Anesthesiology 2001;95:842-
848.
[23]Iyer RA, Baggs RB, Anders MW. Nephrotoxicity of the glutathione
and cysteine S-conjugates of the sevoflurane degradation product 2-
( fluoromethoxy)-1,1,3,3, 3-pentafluoro-1-propene (Compound A) in
[24]Litz RJ, Hübner M, Lorenz W, Meier VK, Albrecht DM. Renal re-
sponses to desflurane and isoflurane in patients with renal insufficiency.
Anesthesiology 2002;97:1133-1136.
fects of desflurane on liver microcirculation in comparison with isoflu-
rane and pentobarbital. An intravital microscopy study in the rat. Ana-
H. Tekrarlanan halotan izofluran ve sevofluran anestezisinin fare ka-

Cite this article as: